284 related articles for article (PubMed ID: 30035417)
1. [Sensitivity and specificity of urinary and serum neurotrophins in the diagnosis of neurogenic detrusor overactivity in multiple sclerosis].
Bazhenov IV; Filippova ES; Bazarnyi VV; Sazonov SV; Volkova LI; Zaitseva LN
Urologiia; 2018 Jul; (3):44-48. PubMed ID: 30035417
[TBL] [Abstract][Full Text] [Related]
2. Impact of intradetrusor botulinum toxin A injections on serum and urinary concentrations of nerve growth factor and brain-derived neurotrophic factor in patients with multiple sclerosis and neurogenic detrusor overactivity.
Philippova ES; Bazhenov IV; Ziryanov AV; Bazarny VV
Neurourol Urodyn; 2021 Jan; 40(1):95-101. PubMed ID: 33034916
[TBL] [Abstract][Full Text] [Related]
3. Urinary biomarkers profiles in patients with neurogenic detrusor overactivity according to their neurological condition.
Richard C; Bendavid C; Hascoet J; Alimi Q; Khene ZE; Kerdraon J; Voiry C; Brochard C; Bouguen G; Siproudhis L; Manunta A; Gamé X; Peyronnet B
World J Urol; 2020 Sep; 38(9):2261-2268. PubMed ID: 31741027
[TBL] [Abstract][Full Text] [Related]
4. Urinary nerve growth factor level in children with neurogenic bladder due to myelomeningocele.
Korzeniecka-Kozerska A; Porowski T; Michaluk-Skutnik J; Wasilewska A; Płoński G
Scand J Urol; 2013 Oct; 47(5):411-7. PubMed ID: 23301927
[TBL] [Abstract][Full Text] [Related]
5. Urinary biomarkers in patients with detrusor underactivity with and without bladder function recovery.
Chen SF; Jiang YH; Kuo HC
Int Urol Nephrol; 2017 Oct; 49(10):1763-1770. PubMed ID: 28770419
[TBL] [Abstract][Full Text] [Related]
6. Value of Urinary Brain-Derived Neurotrophic Factor Levels on the Assessment of Botulinum Toxin Type A Treatment for Neurogenic Detrusor Overactivity in Children with Myelodysplasia.
Sekerci CA; Tanidir Y; Toprak T; Basok BI; Isman F; Simsek F; Akbal C; Tarcan T
J Urol; 2019 Jan; 201(1):174-180. PubMed ID: 30577408
[TBL] [Abstract][Full Text] [Related]
7. Nerve growth factor does not seem to be a biomarker for neurogenic lower urinary tract dysfunction after spinal cord injury.
Krebs J; Pavlicek D; Stoyanov J; Pannek J; Wöllner J
Neurourol Urodyn; 2017 Mar; 36(3):659-662. PubMed ID: 26950046
[TBL] [Abstract][Full Text] [Related]
8. The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA-1, TIMP-2 levels in children with neurogenic detrusor overactivity due to myelodysplasia.
Top T; Sekerci CA; Isbilen-Basok B; Tanidir Y; Tinay I; Isman FK; Akbal C; Simsek F; Tarcan T
Neurourol Urodyn; 2017 Sep; 36(7):1896-1902. PubMed ID: 28090659
[TBL] [Abstract][Full Text] [Related]
9. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?
Seth JH; Sahai A; Khan MS; van der Aa F; de Ridder D; Panicker JN; Dasgupta P; Fowler CJ
BJU Int; 2013 Mar; 111(3):372-80. PubMed ID: 23444927
[TBL] [Abstract][Full Text] [Related]
10. [NERVE GROWTH FACTOR IN THE URINE OF PATIENTS WITH IDIOPATHIC DETRUSOR OVERACTIVITY AND OVERACTIVE BLADDER WITHOUT DETRUSOR OVERACTIVITY].
Krivoborodov GG; Kolesanova EF; Tur EI; Efremov NS
Urologiia; 2015; (3):19-22. PubMed ID: 26390554
[TBL] [Abstract][Full Text] [Related]
11. Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder.
Wang LW; Han XM; Chen CH; Ma Y; Hai B
Int Urol Nephrol; 2014 Feb; 46(2):341-7. PubMed ID: 23982767
[TBL] [Abstract][Full Text] [Related]
12. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder.
Yokoyama T; Kumon H; Nagai A
Neurourol Urodyn; 2008; 27(5):417-20. PubMed ID: 17924444
[TBL] [Abstract][Full Text] [Related]
13. The profile of urinary biomarkers in overactive bladder.
Rada MP; Ciortea R; Măluţan AM; Doumouchtsis SK; Bucuri CE; Clim A; Roman A; Mihu D
Neurourol Urodyn; 2020 Nov; 39(8):2305-2313. PubMed ID: 32813897
[TBL] [Abstract][Full Text] [Related]
14. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection.
Liu HT; Chancellor MB; Kuo HC
Eur Urol; 2009 Oct; 56(4):700-6. PubMed ID: 18472208
[TBL] [Abstract][Full Text] [Related]
15. What is the role for biomarkers for lower urinary tract disorders? ICI-RS 2013.
Fry CH; Sahai A; Vahabi B; Kanai AJ; Birder LA
Neurourol Urodyn; 2014 Jun; 33(5):602-5. PubMed ID: 24436105
[TBL] [Abstract][Full Text] [Related]
16. Urinary TIMP-2 and MMP-2 are significantly associated with poor bladder compliance in adult patients with spina bifida.
Peyronnet B; Richard C; Bendavid C; Naudet F; Hascoet J; Brochard C; Senal N; Jezequel M; Alimi Q; Khene ZE; Corlu A; Clément B; Siproudhis L; Bouguen G; Kerdraon J; Manunta A; Gamé X
Neurourol Urodyn; 2019 Nov; 38(8):2151-2158. PubMed ID: 31486131
[TBL] [Abstract][Full Text] [Related]
17. [Overactive bladder: urodynamic characteristics of detrusor overactivity due to the etiology of low urinary tract dysfun- ction].
Philippova ES; Bazhenov IV; Ziryanov AV; Zhuravlev VN
Urologiia; 2021 Jun; (3):39-44. PubMed ID: 34251099
[TBL] [Abstract][Full Text] [Related]
18. Can urinary nerve growth factor and bladder wall thickness correlation in children have a potential role to predict the outcome of non-monosymptomatic nocturnal enuresis?
Telli O; Samancı C; Sarıcı H; Hascıcek AM; Kabar M; Eroglu M
J Pediatr Urol; 2015 Oct; 11(5):265.e1-5. PubMed ID: 26051999
[TBL] [Abstract][Full Text] [Related]
19. Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome.
Silva-Ramos M; Silva I; Oliveira O; Ferreira S; Reis MJ; Oliveira JC; Correia-de-Sá P
PLoS One; 2013; 8(5):e64696. PubMed ID: 23741373
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of nerve growth factor in detrusor overactivity: a study on women with mixed urinary incontinence.
Salehi-Pourmehr H; Ghojazadeh M; Jahantabi E; Hajebrahimi S
Int Urol Nephrol; 2021 Aug; 53(8):1557-1562. PubMed ID: 33866484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
